What is Agalsidase beta Intravenous
Agalsidase beta is the recombinant form of human alpha-galactosidase A enzyme, which is used to treat Fabry disease. Fabry disease is a rare genetic disorder that affects the way the body processes certain fats. These fats, called globotriaosylceramide (GL-3), can build up and damage certain organs, including the heart, kidneys, and nervous system. Agalsidase beta is used to break down GL-3 and reduce its harmful effects.
Benefits of Agalsidase beta Intravenous
and Its Uses.
Agalsidase beta (trade name Replagal) is a recombinant form of the enzyme agalsidase beta, which is used to treat Fabry disease. Fabry disease is a rare, inherited lysosomal storage disorder caused by a deficiency of the enzyme agalsidase beta, which leads to the accumulation of globotriaosylceramide (GL-3) in tissues. Agalsidase beta is used to remove GL-3 from tissues, which reduces the symptoms of Fabry disease.
Intravenous agalsidase beta is available as a powder that is reconstituted with sterile water for injection. It is given by intravenous infusion over a period of 1-2 hours.
Intravenous agalsidase beta is used to treat Fabry disease.
Intravenous agalsidase beta may cause side effects, including:
Side Effects and Dosage of Agalsidase beta Intravenous
The enzyme agalsidase beta is used to treat Fabry disease, a rare genetic disorder that affects the way the body processes certain fats. Agalsidase beta is a man-made form of the naturally occurring enzyme agalsidase alpha. Agalsidase beta is injected into a vein (intravenous).
Common side effects of agalsidase beta include:
Rare but serious side effects include:
– Allergic reaction, including hives, swelling of the lips, tongue, or throat, and difficulty breathing
– Severe chest pain
– Difficulty breathing
– Sudden and severe pain in the stomach
The most common dosage of agalsidase beta is 1 mg per kilogram of body weight, injected into a vein (intravenous) every other day.